# Pasithea Therapeutics Announces Closing of $60 Million Public Offering of Common Stock
Canonical URL: https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-closing-of-60-million-public-offering-of-common-stock
Ticker: KTTA
Company: Pasithea Therapeutics
Source: Pasithea Therapeutics
Published: 2025-12-02 12:00 EST
Original Source URL: https://ir.pasithea.com
## Article Body
No article body is available yet.
## Recent Company News
- 2026-07-21 11:00 EST — [Pasithea Therapeutics Announces Presentation of PAS-004 Data to European Society for Medical Oncology (ESMO) Congress 2026](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-presentation-of-pas-004-data-to-european-society-99db076a) — Source: Pasithea Therapeutics
- 2026-07-08 11:02 EST — [Pasithea Therapeutics Announces Participation in B. Riley Securities Mind, Muscle & Vision Summit](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-participation-in-b-riley-securities-mind-muscle--c2ef8757) — Source: Pasithea Therapeutics
- 2026-06-30 11:00 EST — [Pasithea Therapeutics Announces Positive Interim Phase 1 Advanced Cancer Study Data Demonstrating Long-Term Safety and Tolerability, and Durable Clinical Activity in MEK/BRAF-Pretreated Patients, plus Protocol Expansion](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-positive-interim-phase-1-advanced-cancer-study-d-e066723c) — Source: Pasithea Therapeutics
- 2026-06-16 11:00 EST — [Pasithea Therapeutics Announces Amendments to Clinical Study Protocol for Phase 1/1B NF1 Clinical Trial](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-amendments-to-clinical-study-protocol-for-phase--66feaf01) — Source: Pasithea Therapeutics
- 2026-06-15 11:02 EST — [Pasithea Therapeutics Announces Exhibit at Children’s Tumor Foundation 2026 NF Conference](https://biopharmsignal.com/news/KTTA/pasithea-therapeutics-announces-exhibit-at-children-s-tumor-foundation-2026-nf-c-c12a7718) — Source: Pasithea Therapeutics
## Related News
- 2026-07-29 14:05 EST — CAPR — [The Lancet Publishes HOPE-3 Data for Capricor Therapeutics’ Deramiocel in Duchenne Muscular Dystrophy](https://biopharmsignal.com/news/CAPR/the-lancet-publishes-hope-3-data-for-capricor-therapeutics-deramiocel-in-duchenn-9e6e6bd9)
- 2026-07-29 13:00 EST — ENLV — [Enlivex Management to Host Webinar to Discuss Capital Strategy, Rain Protocol Treasury Strategy, and Recent Clinical Milestones](https://biopharmsignal.com/news/ENLV/enlivex-management-to-host-webinar-to-discuss-capital-strategy-rain-protocol-tre-5921a627)
- 2026-07-29 12:30 EST — PRGO — [Perrigo to Present at the Canaccord 46th Annual Growth Conference](https://biopharmsignal.com/news/PRGO/perrigo-to-present-at-the-canaccord-46th-annual-growth-conference-40431922)
- 2026-07-29 12:30 EST — LIXT — [NOMAD Announces Operational Deployment of Two Mobile Battery Systems by DSO Electric Cooperative](https://biopharmsignal.com/news/LIXT/nomad-announces-operational-deployment-of-two-mobile-battery-systems-by-dso-elec-7fc12a2c)
- 2026-07-29 12:30 EST — RNXT — [RenovoRx to Host Second Quarter 2026 Financial Results and Business Highlights Conference Call on August 12th at 4:30 p.m. ET](https://biopharmsignal.com/news/RNXT/renovorx-to-host-second-quarter-2026-financial-results-and-business-highlights-c-8bed10ec)